PCAB-based H.pylori eradication study for patients with penicillin allergy

PCAB-based H.pylori eradication study for patients with penicillin allergy - PCAB-based H.pylori eradication study for patients with penicillin allergy (CAP-pen study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016335

Enrollment

Registered

2015-02-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Clarithromycin(CAM) + metronidazole(MNZ) + P-CAB (first line eradication) Metronidazole(MNZ) + sitafloxacin (STFX) + P-CAB (second line eradication)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Penicillin allergic patients with H.pylori infection who want to take eradication treatment. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Past history of taking second line H.pylori eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
The H.pylori eradication rate of Clarithromycin(CAM) + metronidazole(MNZ) + P-CAB (first line) and metronidazole(MNZ) + sitafloxacin(STFX) + P-CAB (second line) for patients with penicillin allergy.	—

Secondary

Measure	Time frame
To evaluate the safety of the two regimens for patients with penicillin allergy.	—

Countries

Japan

Contacts

Public ContactSoichiro Sue

Yokohama City University Hospital Gastroenterology

ssue@yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026